These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
156 related articles for article (PubMed ID: 28471656)
21. Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non-small cell lung cancer: In vitro and in vivo. Zhang GN; Zhang YK; Wang YJ; Gupta P; Ashby CR; Alqahtani S; Deng T; Bates SE; Kaddoumi A; Wurpel JND; Lei YX; Chen ZS Cancer Lett; 2018 Jun; 424():19-29. PubMed ID: 29518481 [TBL] [Abstract][Full Text] [Related]
22. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043 [TBL] [Abstract][Full Text] [Related]
24. Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes. To KKW; Wu X; Yin C; Chai S; Yao S; Kadioglu O; Efferth T; Ye Y; Lin G J Ethnopharmacol; 2017 May; 203():110-119. PubMed ID: 28363522 [TBL] [Abstract][Full Text] [Related]
25. Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway. Pick A; Wiese M ChemMedChem; 2012 Apr; 7(4):650-62. PubMed ID: 22354538 [TBL] [Abstract][Full Text] [Related]
26. β-carotene reverses multidrug resistant cancer cells by selectively modulating human P-glycoprotein function. Teng YN; Sheu MJ; Hsieh YW; Wang RY; Chiang YC; Hung CC Phytomedicine; 2016 Mar; 23(3):316-23. PubMed ID: 26969385 [TBL] [Abstract][Full Text] [Related]
27. The combination of quinazoline and chalcone moieties leads to novel potent heterodimeric modulators of breast cancer resistance protein (BCRP/ABCG2). Kraege S; Stefan K; Juvale K; Ross T; Willmes T; Wiese M Eur J Med Chem; 2016 Jul; 117():212-29. PubMed ID: 27100033 [TBL] [Abstract][Full Text] [Related]
29. A Phenylfurocoumarin Derivative Reverses ABCG2-Mediated Multidrug Resistance In Vitro and In Vivo. Kokubo S; Ohnuma S; Murakami M; Kikuchi H; Funayama S; Suzuki H; Kajiwara T; Yamamura A; Karasawa H; Sugisawa N; Ohsawa K; Kano K; Aoki J; Doi T; Naitoh T; Ambudkar SV; Unno M Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830383 [TBL] [Abstract][Full Text] [Related]
30. Synthetic Analogs of Curcumin Modulate the Function of Multidrug Resistance-Linked ATP-Binding Cassette Transporter ABCG2. Murakami M; Ohnuma S; Fukuda M; Chufan EE; Kudoh K; Kanehara K; Sugisawa N; Ishida M; Naitoh T; Shibata H; Iwabuchi Y; Ambudkar SV; Unno M Drug Metab Dispos; 2017 Nov; 45(11):1166-1177. PubMed ID: 28904007 [TBL] [Abstract][Full Text] [Related]
31. Pyrrolopyrimidine Derivatives as Novel Inhibitors of Multidrug Resistance-Associated Protein 1 (MRP1, ABCC1). Schmitt SM; Stefan K; Wiese M J Med Chem; 2016 Apr; 59(7):3018-33. PubMed ID: 26943020 [TBL] [Abstract][Full Text] [Related]
32. ABCG2 inhibition as a therapeutic approach for overcoming multidrug resistance in cancer. Hasanabady MH; Kalalinia F J Biosci; 2016 Jun; 41(2):313-24. PubMed ID: 27240991 [TBL] [Abstract][Full Text] [Related]
33. β-Casein micelles for oral delivery of SN-38 and elacridar to overcome BCRP-mediated multidrug resistance in gastric cancer. Bar-Zeev M; Kelmansky D; Assaraf YG; Livney YD Eur J Pharm Biopharm; 2018 Dec; 133():240-249. PubMed ID: 30367935 [TBL] [Abstract][Full Text] [Related]
34. Overexpression of ABCG2 confers resistance to pevonedistat, an NAE inhibitor. Wei LY; Wu ZX; Yang Y; Zhao M; Ma XY; Li JS; Yang DH; Chen ZS; Fan YF Exp Cell Res; 2020 Mar; 388(2):111858. PubMed ID: 31972220 [TBL] [Abstract][Full Text] [Related]
35. A new porphyrin as selective substrate-based inhibitor of breast cancer resistance protein (BCRP/ABCG2). Zattoni IF; Kronenberger T; Kita DH; Guanaes LD; Guimarães MM; de Oliveira Prado L; Ziasch M; Vesga LC; Gomes de Moraes Rego F; Picheth G; Gonçalves MB; Noseda MD; Ducatti DRB; Poso A; Robey RW; Ambudkar SV; Moure VR; Gonçalves AG; Valdameri G Chem Biol Interact; 2022 Jan; 351():109718. PubMed ID: 34717915 [TBL] [Abstract][Full Text] [Related]
36. Flavonoid Monomers as Potent, Nontoxic, and Selective Modulators of the Breast Cancer Resistance Protein (ABCG2). Wong ILK; Zhu X; Chan KF; Liu Z; Chan CF; Chow TS; Chong TC; Law MC; Cui J; Chow LMC; Chan TH J Med Chem; 2021 Oct; 64(19):14311-14331. PubMed ID: 34606270 [TBL] [Abstract][Full Text] [Related]
37. Afatinib circumvents multidrug resistance via dually inhibiting ATP binding cassette subfamily G member 2 in vitro and in vivo. Wang XK; To KK; Huang LY; Xu JH; Yang K; Wang F; Huang ZC; Ye S; Fu LW Oncotarget; 2014 Dec; 5(23):11971-85. PubMed ID: 25436978 [TBL] [Abstract][Full Text] [Related]
38. Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS-032 with ABCB1, ABCG2 and ABCC1 transporters and their potential to overcome multidrug resistance in vitro. Cihalova D; Staud F; Ceckova M Cancer Chemother Pharmacol; 2015 Jul; 76(1):105-16. PubMed ID: 25986678 [TBL] [Abstract][Full Text] [Related]
39. Benzoyl indoles with metabolic stability as reversal agents for ABCG2-mediated multidrug resistance. Cai CY; Zhai H; Lei ZN; Tan CP; Chen BL; Du ZY; Wang JQ; Zhang YK; Wang YJ; Gupta P; Wang B; Chen ZS Eur J Med Chem; 2019 Oct; 179():849-862. PubMed ID: 31302589 [TBL] [Abstract][Full Text] [Related]
40. Triazole Bridged Flavonoid Dimers as Potent, Nontoxic, and Highly Selective Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibitors. Zhu X; Wong ILK; Chan KF; Cui J; Law MC; Chong TC; Hu X; Chow LMC; Chan TH J Med Chem; 2019 Sep; 62(18):8578-8608. PubMed ID: 31465686 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]